Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Thursday, February 2, 2017

Stroke Caused by Atherosclerosis of the Major Intracranial Arteries

Damn, more lazy meta-analysis rather than actually doing some work and solving some of the fucking problems in stroke. Lazy assholes.
http://circres.ahajournals.org/content/120/3/502?etoc=
Chirantan Banerjee, Marc I. Chimowitz

Abstract

Our goal in this review is to discuss the pathophysiology, diagnosis, and treatment of stroke caused by atherosclerosis of the major intracranial arteries. References for the review were identified by searching PubMed for related studies published from 1955 to June 2016 using search terms intracranial stenosis and intracranial atherosclerosis. Reference sections of published randomized clinical trials and previously published reviews were searched for additional references. Intracranial atherosclerotic disease is a highly prevalent cause of stroke that is associated with a high risk of recurrent stroke. It is more prevalent among blacks, Hispanics, and Asians compared with whites. Diabetes mellitus, hypertension, metabolic syndrome, smoking, hyperlipidemia, and a sedentary lifestyle are the major modifiable risk factors associated with intracranial atherosclerotic disease. Randomized clinical trials comparing aggressive management (dual antiplatelet treatment for 90 days followed by aspirin monotherapy and intensive management of vascular risk factors) with intracranial stenting plus aggressive medical management have shown medical management alone to be safer and more effective for preventing stroke. As such, aggressive medical management has become the standard of care for symptomatic patients with intracranial atherosclerotic disease. Nevertheless, there are subgroups of patients who are still at high risk of stroke despite being treated with aggressive medical management. Future research should aim to establish clinical, serological, and imaging biomarkers to identify high-risk patients, and clinical trials evaluating novel therapies should be focused on these patients.

Introduction

Atherosclerosis in major intracranial arteries leads to changes ranging from minor wall thickening to hemodynamically significant luminal stenosis and is one of the most common causes of stroke worldwide.1 Intracranial atherosclerotic disease (ICAD) may occur concomitantly with systemic atherosclerosis involving other arterial beds, such as extracranial, coronary, or peripheral arteries, or may occur in isolation.2,3 The middle cerebral arteries (MCAs) are the most common site, followed by the basilar artery, the internal carotid arteries, and the intracranial vertebral arteries.4,5 ICAD is highly prevalent in black, Asian (China, Japan, South Korea, and India), and Hispanic populations.1 As these populations are major drivers of global population growth, the global stroke burden from ICAD is expected to rise over time.
Clinical trials in the last decade have improved our understanding of the high stroke recurrence rate in ICAD, risk factors, and neuroimaging biomarkers associated with recurrence, as well as ushered in therapeutic changes. In this study, we review the epidemiology, risk factors, pathophysiology, diagnosis and management of ICAD.

More at link.

No comments:

Post a Comment